 | February 1, 2012
By:Ben Comer
Bausch + Lomb CEO Brent Saunders refocuses on the customer.
 |
 | February 1, 2012
By:William Looney
A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.
|
 | February 1, 2012
By:Sarah Krüg
Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust.
|
 | February 1, 2012
By:Ben Comer
Rich data on the clinical side, combined with flexible marketing and outreach to payers, have pushed Humira to the top ranks of powerhouse drugs...
|
 | January 1, 2012
By:William Looney
The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
|
 | January 1, 2012
By:Nathan Jessop
The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales.
|
 | January 1, 2012
William Looney looks at how Big Pharma is attempting to bridge the emerging markets' widening cancer divide.
|
 | January 1, 2012
How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all?
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
